Novavax, Inc. Earnings Recaps
Q1 2026
May 7, 2026
Shares rose 14.0% as the market rewarded Novavax’s clear progress in expanding high-value partnerships, particularly with big pharma like Pfizer and Sanofi, signaling confidence in its capital-efficient, licensing-driven growth strategy rather than direct product sales.
Key takeaways
- Novavax signed four new material transfer agreements (MTAs) including a significant oncology MTA with a top 10 global pharma company, marking expanded collaboration in difficult cancer targets.
- The company’s partnerships with Pfizer and Sanofi are positioned to generate billions in future milestone and royalty revenues, with Sanofi already contributing over $800 million in revenue to date.
- Strategy emphasizes capital-efficient growth by leveraging partners’ infrastructure and investment, reducing Novavax’s operational costs while focusing on R&D-led innovation.
- Management outlined a lean operating model aimed at driving down costs while supporting key R&D capabilities under new Head of R&D Bob Walker.
- The outlook centers on advancing current partnerships to clinical readiness and converting MTAs into licensing agreements, supporting long-term, diversified revenue streams.
Q3 2025
Nov 6, 2025
Novavax demonstrated significant progress in Q3 2025, strengthening its partnership strategies and advancing its diversified R&D pipeline while achieving substantial cash flow, underscoring a shift towards long-term profitability and growth.
Key takeaways
- Achieved approximately $1.1 billion in nondilutive cash flow over 8 quarters, bolstered by $800 million from partnerships.
- Successfully secured $225 million from Sanofi-related milestones, including key regulatory approvals for Nuvaxovid.
- Launched new early-stage R&D initiatives targeting infectious diseases and oncology, emphasizing a diversified pipeline beyond COVID-19.
- Initiated cost-saving measures, including consolidating facilities to enhance financial strength, projected to save approximately $230 million.
- Positioned to potentially reach non-GAAP profitability by 2028 through a revamped revenue mix driven by partnerships and royalties.